Generated: December 16, 2017
DrugPatentWatch Database Preview
Details for Patent: 4,992,474
« Back to Dashboard
Summary for Patent: 4,992,474
|Title:|| Phenethanolamine derivatives|
|Abstract:||Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12; Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group; R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof. The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients. The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.|
|Inventor(s):|| Skidmore; Ian F. (Welwyn, GB2), Lunts; Lawrence H. C. (Broxbourne, GB2), Finch; Harry (Hitchin, GB2), Naylor; Alan (Royston, GB2) |
|Assignee:|| Glaxo Group Ltd. (London, GB2) |
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use; |
No matches for this query
Foreign Priority and PCT Information for Patent: 4,992,474
|Foriegn Application Priority Data|
||Foreign Patent Number
||Foreign Patent Date
|United Kingdom||8310477||Apr 18, 1983|
|United Kingdom||8317087||Jun 23, 1983|
|United Kingdom||8329568||Nov 04, 1983|
|United Kingdom||8401889||Jan 25, 1984|
International Patent Family for Patent: 4,992,474
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.